United Therapeutics (UTHR) Receives Media Impact Rating of 0.21

Headlines about United Therapeutics (NASDAQ:UTHR) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. United Therapeutics earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.6395354137617 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the headlines that may have effected Accern’s scoring:

United Therapeutics (NASDAQ:UTHR) traded down $0.04 during trading on Friday, reaching $149.79. 365,600 shares of the company traded hands, compared to its average volume of 371,747. United Therapeutics has a 12-month low of $112.01 and a 12-month high of $169.89. The stock has a market cap of $6,472.58, a P/E ratio of 13.21 and a beta of 1.41.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million for the quarter, compared to the consensus estimate of $426.43 million. During the same quarter in the previous year, the firm posted $4.23 EPS. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. analysts forecast that United Therapeutics will post 12.96 EPS for the current year.

UTHR has been the topic of a number of research reports. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. ValuEngine raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 30th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Cowen reissued a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a research note on Friday, October 27th. Finally, HC Wainwright reissued a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a research note on Thursday, October 26th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. United Therapeutics has a consensus rating of “Hold” and an average price target of $138.50.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,265 shares of the firm’s stock in a transaction on Thursday, October 19th. The shares were sold at an average price of $119.38, for a total transaction of $151,015.70. Following the completion of the transaction, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at approximately $167,728.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,263 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $120.20, for a total transaction of $151,812.60. The disclosure for this sale can be found here. Insiders have sold a total of 17,036 shares of company stock worth $2,077,449 in the last ninety days. 7.80% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://stocknewstimes.com/2018/01/08/united-therapeutics-uthr-receives-media-impact-rating-of-0-21.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply